HIV Clinical Trial
Official title:
Effectiveness and Tolerability of Hepatitis C Treatment in HIV Co-infected Patients in Routine Care Services in Asia: A Pilot Model of Care Project
The purpose of this study is to assess the effectiveness and tolerability of hepatitis C virus (HCV) treatment in HIV co-infected patients in routine health care services in Asia through a pilot model of care for treatment of HCV in resource-limited settings.
Status | Completed |
Enrollment | 188 |
Est. completion date | September 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - 18 years of age or older - Confirmed HIV infection by antibody and/or virologic testing - Chronic HCV infection with any genotype, confirmed by a positive anti-HCV antibody test obtained at least six months prior to screening, and detectable HCV RNA at screening. - Stable ART in patients with CD4 counts between 200-350 cells/µl at the time of screening, OR stable ART, or no ART in patients with CD4 counts above 350 cells/µl at the time of screening. - Liver fibrosis stage >F1 (defined as a fibrosis score >=7.5 KPa by Fibroscan®, or through histological examination of a liver biopsy specimen). - Compensated liver disease, with a Child-Pugh grade no greater than A, and: - No ascites (current or ever) - No hepatic encephalopathy (current or ever) - No bleeding varices (current or ever) - Patients with suspected cirrhosis (Fibroscan® >=13.0 KPa or through histological examination of a liver biopsy specimen) must have an abdominal ultrasound and alpha fetoprotein test result without evidence of hepatocellular carcinoma within two months prior to screening. - Negative urine or blood pregnancy test for women of childbearing potential documented within the 24-hour period prior to the first dose of study drug. - All males and females of reproductive age and potential must agree to use effective contraception during treatment and during the 24 weeks after the end of treatment. - Voluntarily signed informed consent form. - Willingness to start therapy and to adhere to the requirements of the study visits schedule. Exclusion Criteria: - Any history of previous Interferon or ribavirin therapy. - Known active bacterial infection. - Ongoing treatment for mycobacterial infection. - CD4 count <200 cells/ µl. - Current pregnancy or breast feeding. - Male partners of women who are pregnant. - Evidence of a medical condition other than HCV identified as another significant cause of chronic liver disease (e.g., severe alcoholic liver disease, toxin exposures, metabolic liver disease, autoimmune hepatitis). - Active drug use or alcohol consumption that is judged by the study physician to potentially compromise treatment safety. - Hemoglobin <11 g/dL in women or <12 g/dL in men. - ALT (SGPT) or AST (SGOT) level >10 times the upper normal limit. - Neutrophil count <1500 cells/mm3 or platelet count <90,000 cells/mm3. - Serum creatinine level >1.5 times the upper normal limit. - Inadequately controlled thyroid dysfunction (i.e., TSH and T4 levels out of normal ranges). - Ongoing severe psychiatric disease (e.g., depression) as judged by the study physician to potentially compromise treatment safety. - Uncontrolled seizure disorder. - Concomitant use of didanosine. - Evidence of severe retinopathy (e.g. CMV retinitis, macular degeneration) or clinically relevant ophthalmological disorder due to diabetes mellitus or hypertension. - History of severe chronic pulmonary disease, cardiac disease, malignancy, or other severe illness, which would make the patient, in the opinion of the study physician, unsuitable for treatment administration and participation in the study. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Indonesia | Cipto Mangunkusumo General Hospital | Jakarta | |
Malaysia | University of Malaya Medical Centre | Kuala Lumpur | |
Thailand | HIV-NAT/ Thai Red Cross AIDS Research Center | Bangkok | |
Vietnam | National Hospital for Tropical Diseases | Hanoi |
Lead Sponsor | Collaborator |
---|---|
amfAR, The Foundation for AIDS Research | Kirby Institute |
Indonesia, Malaysia, Thailand, Vietnam,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The proportion of patients with sustained virological response (SVR), defined as an undetectable HCV RNA, 24 weeks after completion of therapy | 24 weeks after completion of therapy | No | |
Secondary | Proportion of patients with Rapid Virological Response (RVR) | 4 weeks of therapy | No | |
Secondary | Proportion of patients with Early Virological Response (EVR) | 12 weeks of therapy | No | |
Secondary | Proportion of patients with End of Treatment Response (ETR) | Up to 48 weeks of therapy | No | |
Secondary | Proportions of patients who discontinue treatment prematurely | Up to 48 weeks of therapy | Yes | |
Secondary | Clinical and laboratory safety parameters | The proportion of participants with all grades of adverse events will be summarized by severity and relation to study drugs. | Up to 48 weeks of therapy | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |